Entering text into the input field will update the search result below

Galectin Therapeutics and Providence Cancer Institute nab new patent in U.S.

  • Galectin Therapeutics (NASDAQ:GALT) and Providence Cancer Institute have received notice of issuance of U.S. Patent Number 10,398,778 titled "Method for Enhancing Specific Immunotherapies in Cancer Treatment.”
  • The patent, in effect until 2033, covers method of use of Company's drug candidate, belapectin (GR-MD-02), as a means to enhance the effectiveness of specific immunotherapies in cancer treatment.

Recommended For You

About GALT Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
GALT--
Galectin Therapeutics Inc.